Difference between revisions of "Part:BBa K3784005"
(→Characterization) |
|||
Line 18: | Line 18: | ||
− | [[File:BNUZ-gp2.png]] | + | [[File:BNUZ-gp2.png|2000px]] |
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here |
Revision as of 11:43, 17 October 2021
bg2 (Encoding β-galactosidase)
Patients with CKD are often accompanied by intestinal flora imbalance, and the number, composition, distribution and structure of intestinal flora have changed, which is manifested by the decrease of beneficial bacteria and the abnormal proliferation of pathogenic bacteria and conditional pathogens.
Therefore, we hope that our engineered bacteria can regulate the colony structure of the intestines, promote the proliferation of lactobacilli, bifidobacteria and other probiotics, and inhibit the proliferation of pathogenic bacteria such as Clostridium sporogenes. And galactooligosaccharide(GOS) is a very good choice. Studies have shown that galactooligosaccharide has a very good ability to promote the proliferation of intestinal probiotics such as bifidobacteria and lactobacilli, and it can inhibit the proliferation of intestinal pathogenic bacteria such as Clostridium sporogenes and reduce the production of intestinal endotoxins. At the same time, galactooligosaccharides can alleviate the intestinal inflammation caused by LPS stimulation and enhance the human intestinal barrier function.
We have heterologously expressed the β-galactosidase bga2 of strain Klebsiella oxytoca ZJUH1705 in the engineered bacteria. It has been confirmed that this enzyme has up to 45% of the ability to catalyze lactose to form galacto-oligosaccharides. This is a very high catalytic ability.
Characterization
To test whether our engineering bacteria can transcribe and encode the gene of β-galactosidase, we transformed the plasmid into E.coli BL21(DE3) and induced its expression. After the total RNA was extracted, the cDNA was obtained by reverse transcription. We use cDNA as a template to amplify each fragment, then check whether there is our target band by agarose gel electrophoresis. We chose rsmA (16S rRNA m(6)2A1518, m(6)2A1519 dimethyltransferase) as the reference gene and set a negative control. GOS was well expressed and the corresponding mRNA was successfully transcribed. The expression levels of reference genes in the experimental group (rsmAE) and the control group (rsmAC) were consistent.
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 1708
- 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 1708
- 21COMPATIBLE WITH RFC[21]
- 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 1708
- 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 1708
Illegal NgoMIV site found at 176
Illegal NgoMIV site found at 1323 - 1000COMPATIBLE WITH RFC[1000]